Find out more about our research and development
 
OUR LATEST NEWS

Jan 16, 2017


Warrant Expiry – Reminder

Update in respect of the series “B” warrants issued to investors on 18 June 2014 (“Warrants”), in connection with a fundraising by the Company.

Read more »


Jan 3, 2017


Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL- 6R monoclonal antibody

Exclusive world-wide license expands therapeutic pipeline in key immunological areas.

Read more »


All our latest news »

 

AUTOIMMUNE DISEASES

IBD, TYPE I DIABETES & LUPUS


We have acquired foralumab, a fully human anti-CD3 antibody a unique asset for treatment of autoimmune diseases such as ulcerative colitis, inflammatory bowel diseases, type I diabetes, lupus and others. We anticipate filing an IND in 2016.


Find out more »

 
 

BREAST CANCER

INCLUDING TRIPLE NEGATIVE BREAST CANCER


We have acquired a specific inhibitor of Bcl-3 function from Cardiff University capable of inhibiting triple-negative, HER-2-positive and ER-positive breast cancer metastases. We anticipate filing an IND in 2016.



Find out more »

 
 

THYMIC & LIVER CANCER

ORPHAN DRUG STATUS


We are focusing on a late stage CDK inhibitor, milciclib for thymoma cancer which has orphan drug status. milciclib is currently in late Phase II study for thymoma. This candidate may have potential in other cancer, such as liver carcinoma and breast cancer.


Find out more »

 
 

Tiziana Life Sciences PLC   | AIM:TILS

TIZIANA RECEIVES Innovation in Healthcare Award